<DOC>
	<DOCNO>NCT01050946</DOCNO>
	<brief_summary>This study mean provide transplantation patient would stem cell transplant candidate appropriate donor . The use CD34 select haploidentical donor umbilical cord unit may help provide early engraftment without need long term immunosuppression . This study test new method bone marrow transplantation call combine haploidentical-cord blood transplantation . In procedure , blood forming cell ( stem cell ) partially human leukocyte antigen ( HLA ) match ( haploidentical ) relate donor collect blood , well cell umbilical cord transplant patient ( recipient ) administration `` condition regimen '' . A condition regimen consist chemotherapy sometimes radiation entire body ( total body irradiation , TBI ) , meant destroy cancer cell suppress recipient 's immune system allow transplant cell take ( grow ) .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation ( HSCT ) Using CD34 Selected Mismatched Related Donor One Umbilical Cord Unit</brief_title>
	<detailed_description>This method stem cell transplantation design overcome limitation alternative donor transplant option . Use unrelated umbilical cord unit ( UCB ) donor appear allow great degree HLA mismatch acceptable rate GVHD . However , UCB transplant study adult population , investigator discover several limitation . One major limitation UCB delay engraftment , result high risk infection early post transplant period . The limitation cord blood transplant involve delay engraftment result early complication infection . The main limitation associate haploidentical donor significant immunosuppression require prevent/treat aGVHD . Use combine modality transplantation appear allow rapid neutrophil engraftment haploidentical donor couple long term hematopoiesis UCB donor , thus require less long term immunosuppression . This study test new method bone marrow transplantation call combine haploidentical-cord blood transplantation . In procedure , blood forming cell ( stem cell ) partially HLA match ( haploidentical ) relate donor collect blood , well cell umbilical cord transplant patient ( recipient ) administration `` condition regimen '' . A condition regimen consist chemotherapy sometimes radiation entire body ( total body irradiation , TBI ) , One two 'conditioning regimen ' determine physician . 1 . FLUDARABINE , MELPHALAN , ATG Fludarabine 30mg/m2 ( Days-7 , -6 , -5 , -4 , -3 ) - , Melphalan 70mg/m2 ( Day -3 , -2 ) , ATG 1.5mg/m2 ( Day-7 , -5 , -3 , -1 ) 2 . FLUDARABINE , BUSULFAN , 400 CGY TBI , ATG Fludarabine 50mg/m2 ( Day -6 , -5 , -4 , -3 , -2 ) , Busulfan 3.2mg/kg ( Day -5 , -4 , -3 , -2 ) 400cGY Total Body Irradiation ( TBI ) Day-1 , ATG 1.5mg/kg ( Day-7 , -5 , -3 , -1 ) Day 0 -Haploidentical donor one umbilical cord blood unit infusion Filgrastim administer daily day +1 blood count completely recover . Tacrolimus another immunosuppressant , Cellcept , start transplant also reduce risk graft versus host disease promote growth graft . Tacrolimus give daily two day transplant least three month transplantation . Cellcept , taper cell engraft .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients 18 65 year old Patient relate family member ( haploidentical ) unrelated 5 10 HLA identical match . Standard Risk Acute myelogenous leukemia : CR1 high risk cytogenetics molecular abnormality FLT3 ITD , CR2 first remission must last &gt; 1 year . Acute Lymphocytic Leukemia : CR1 , order standard risk must NOT Philadelphia Chromosome . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) : Must refractory fludarabine fail complete partial response therapy regimen contain fludarabine ( another nucleoside analog , e.g . 2CDA , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain fludarabine ( another nucleoside analog ) . Chronic myelogenous leukemia : resistant intolerant TKI , CP1 CP2 , mutation suggest resistance TKI . Myelodysplastic Syndrome : RA , RARS , must IPSS â‰¥ INT2 , Blasts &lt; 5 % . High Risk Patients : Acute myelogenous leukemia : Patients CR2 consider high risk high risk cytogenetics , molecular abnormality CR1 last less 1 year . Any evidence active disease blast acellular marrow . Acute Lymphocytic Leukemia : CR1 Ph+ disease , CR2/+ cytogenetics . Any evidence active disease . Chronic myelogenous leukemia CP2/+ , AP1/+ , resistant intolerant TKI . Hodgkin 's Non Hodgkin 's lymphoma Disease recurrence follow autologous transplant , high risk disease think benefit autologous transplant . Chronic lymphocytic leukemia resistant fludarabine , never remission stable disease/progressive disease Multiple myeloma : Must prior treatment . Patients CR2 great consider , must already fail autologous transplant Previous autologous transplant , must great 6 month prior undergo transplant . Myelodysplastic syndrome : RAEB Other Myeloproliferative disorder include myelofibrosis , spent phase p Vera , Essential thrombocytosis , CMML . Patients &lt; 18 year old Disease relate criterion APML , presence ( 15,17 ) first CR Patients good risk AML , example ( 8 ; 21 ) , inv 16 , normal cytogenetics FLT3ITD negative , NPM1 positive disease 1st CR MDS IPSS &lt; INT2 Miscellaneous Criteria Recipients match related sibling unrelated donor If recipient evidence antiHLA antibody direct cord haplodonor determine byflowPRA . Underlying health criterion : Zubrod performance status &gt; 2 ( see Appendix E ) Life expectancy limit less 8 week concomitant illness Patients severely decrease LVEF ( EF &lt; 40 % ) Impaired pulmonary function test ( PFT 's ) ( FVC , FEV1 , DLCO &lt; 45 % predict ) Estimated Creatinine Clearance &lt; 50 ml/min Serum bilirubin &gt; 2.0 mg/dl SGPT &gt; 3 x upper limit normal Evidence chronic active hepatitis cirrhosis HIVpositive Patient pregnant Patient guardian able provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Unrelated Umbilical Cord Blood Transplant ( UCB )</keyword>
	<keyword>CD34+ Selected mismatch related donor</keyword>
	<keyword>Haploidentical donor</keyword>
	<keyword>hematopoietic stem cell transplantation ( HSCT )</keyword>
	<keyword>ALL</keyword>
	<keyword>Leukemia , Lymphocytic , Acute</keyword>
	<keyword>AML</keyword>
	<keyword>Leukemia , Myelocytic , Acute</keyword>
	<keyword>CML</keyword>
	<keyword>Leukemia , Myeloid , Chronic</keyword>
	<keyword>NHL</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>HL</keyword>
	<keyword>Lymphoma , Hodgkins</keyword>
</DOC>